Adjuvance Technologies Participates in the KORUS Global Vaccine Partnership Event

Sep 22, 2021

Lincoln, NE – September 22, 2021 – Adjuvance Technologies Inc., a privately-held, clinical-stage biopharmaceutical company developing next-generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that it has signed a memorandum of understanding (MOU) with EuBiologics, a South Korean biotech company whose Toll-like Receptor (TLR) four agonist adjuvant EcML® may be used in combination with Adjuvance’s saponin adjuvant TQL-1055.

The MOU describes the intention for EuBiologics to provide EcML for a planned Adjuvance-sponsored Phase 1 clinical trial and for the companies to continue negotiations toward a research and commercialization license agreement to use EcML in combination with Adjuvance’s semi-synthetic saponin adjuvants. During the KORUS Global Vaccine Partnership Event, Adjuvance will participate in the MOU ceremony, a vaccine partnership round table and partnership meetings with participating Korean vaccine companies.

About TQL-1055: TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant. TQL-1055 is designed to have improved tolerability and provide the same strong immune response as QS-21. The efficient synthesis of TQL-1055 uses raw material from leaves and branches of the Quillaja saponaria tree, making it available in greater quantities than the source material for other saponin adjuvants. TQL-1055 has shown favorable tolerability and a strong immune response in a clinical trial. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses.

About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships.

Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn.

About EuBiologics: EuBiologics (KOSDAQ:206650) is a South Korean biotech company specializing in vaccine development and contract research and manufacturing services in vaccine and protein therapeutics. EuBiologics has a licensed cholera vaccine and a pipeline of high-quality vaccines to improve the health of children around the world. For more information visit www.eubiologics.com.

About the KORUS Global Vaccine Partnership: In May of 2021 in a summit meeting between U.S. President Joe Biden and Rep of Korea President Moon Jae-in, the United States and Korea established the KORUS Global Vaccine Partnership. This event has been organized by the Korean Ministry of Trade, Industry and Energy and the Korean Trade-Investment Promotion Agency (KOTRA). For more information visit www.2021vaccinepartnership.com.

Adjuvance Contacts:                                                EuBiologics Contact:
Melissa Malhame                                                       Tae Young Jin
+1 531-530-1287                                                      +82-70-4881-7117

Investors
Tyler Martin
Chief Executive Officer
+1 402-817-5050